预约演示
更新于：2025-07-05
Linezolid
利奈唑胺
更新于：2025-07-05
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-04-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H20FN3O4 |
InChIKeyTYZROVQLWOKYKF-ZDUSSCGKSA-N |
CAS号165800-03-3 |
关联
184
项与 利奈唑胺 相关的临床试验NCT06921213
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
NCT06590428
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
NCT06441006
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)
100 项与 利奈唑胺 相关的临床结果
登录后查看更多信息
100 项与 利奈唑胺 相关的转化医学
登录后查看更多信息
100 项与 利奈唑胺 相关的专利（医药）
登录后查看更多信息
9,261
项与 利奈唑胺 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Genomic islands and molecular mechanisms relating to drug-resistance in
Clostridioides
(
Clostridium
)
difficile
PCR ribotype 176
Article
作者: Soltesova, Anna ; Pituch, Hanna ; Kuijper, Ed ; Brajerova, Marie ; Balikova Novotna, Gabriela ; Prasad, Suhanya ; Zikova, Jaroslava ; Demay, Fanny ; Novakova, Elena ; Kovarovic, Vojtech ; Krutova, Marcela ; Smits, Wiep Klaas
OBJECTIVES:
To analyse characteristics of Clostridioides difficile PCR ribotype 176 clinical isolates from Poland, the Czech Republic and Slovakia with regard to the differences in its epidemiology.
METHODS:
Antimicrobial susceptibility testing and whole genome sequencing were performed on a selected group of 22 clonally related isolates as determined by multilocus variable-number tandem repeat analysis (n = 509). Heterologous expression and functional analysis of the newly identified methyltransferase were performed.
RESULTS:
Core genome multilocus sequence typing found 10-37 allele differences. All isolates were resistant to fluoroquinolones (gyrA_p. T82I), aminoglycosides with aac(6')-Ie-aph(2'')-Ia in six isolates. Erythromycin resistance was detected in 21/22 isolates and 15 were also resistant to clindamycin with ermB gene. Fourteen isolates were resistant to rifampicin with rpoB_p. R505K or p. R505K/H502N, and five to imipenem with pbp1_p. P491L and pbp3_p. N537K. PnimBG together with nimB_p. L155I were detected in all isolates but only five were resistant to metronidazole on chocolate agar. The cfrE, vanZ1 and cat-like genes were not associated with linezolid, teicoplanin and chloramphenicol resistance, respectively. The genome comparison identified six transposons carrying antimicrobial resistance genes. The ermB gene was carried by new Tn7808, Tn6189 and Tn6218-like. The aac(6')-Ie-aph(2'')-Ia were carried by Tn6218-like and new Tn7806 together with cfrE gene. New Tn7807 carried a cat-like gene. Tn6110 and new Tn7806 contained an RlmN-type 23S rRNA methyltransferase, designated MrmA, associated with high-level macrolide resistance in isolates without ermB gene.
CONCLUSIONS:
Multidrug-resistant C. difficile PCR ribotype 176 isolates carry already described and unique transposons. A novel mechanism for erythromycin resistance in C. difficile was identified.
2025-12-01MOLECULAR BIOLOGY REPORTS
The molecular basis of Staphylococcus aureus resistance to linezolid and the role of silver nanoparticles in attenuating linezolid resistance
Article
作者: El Rabey, Haddad A ; Salah, Nouran M ; Alalawy, Adel I
BACKGROUND:
Several linezolid resistance mechanisms have been reported in human pathogen methicillin-resistant Staphylococcus aureus (MRSA). This study investigated the molecular basis of methicillin resistance in S. aureus with increased linezolid minimum inhibitory concentrations (MICs).
METHODS AND RESULTS:
The antimicrobial efficacy of silver nanoparticles (AgNPs) derived from S. aureus and rosemary leaves (Rosmarinus officinalis) was evaluated against linezolid-resistant S. aureus strains. 81% of the isolates were MRSA, and 20% were linezolid resistant. Twelve isolates were linezolid-resistant S. aureus (LRSA) via the agar dilution. Molecular confirmation of linezolid-resistant S. aureus was performed by detecting the nuc gene and sequencing the 16 S rRNA gene. Molecular analysis of the resistant isolates revealed that mutations in domain V of the 23 S rRNA, rplC and rplV genes were detected in all the isolates, whereas the cfr gene was not assigned. DNA sequencing revealed that the major mutation in our isolates was a G to A mutation at different positions despite the presence of the T2500A mutation.
CONCLUSIONS:
AgNPs synthesized from rosemary leaves and S. aureus had a significant antimicrobial effect on LRSA isolates. In addition, the LRSA isolates became sensitive to linezolid after mixing linezolid with the synthesized AgNPs.
2025-10-01ENVIRONMENTAL RESEARCH
Enhanced visible-light photocatalysis of a senary mixture of antibiotics using a low-dose of TiO2–ZnO nanocomposite
Article
作者: Mukherji, Suparna ; Ansari, Arhama T A ; Mukherji, Soumyo
Antibiotics discharged from wastewater treatment plants continue to pose severe environmental and public health risks by promoting antibiotic resistance. While photocatalysis has shown promising degradation of antibiotics, most studies have evaluated single antibiotics at high catalyst doses, limiting the feasibility of practical application. In this study, a TiO2-ZnO nanocomposite (TZ-NC) was synthesized via a modified sol-gel method. A low dose of this TZ-NC was applied to degrade a senary antibiotic mixture comprising erythromycin, azithromycin, linezolid, enrofloxacin, oxacillin, and sulfamethazine under both UV and visible irradiation. Characterization by XRD, FTIR, TEM, and UV-Vis spectroscopy confirmed the formation of a mixed oxide system with improved charge separation and reduced band gap, thereby enabling visible-light activity. Multi-component adsorption experiments revealed selective interactions of TZ-NC with macrolides and fluoroquinolone through electrostatic interactions. Photolysis under UV and visible irradiation resulted in minimal degradation. Under both irradiation conditions, the TZ-NC achieved near-complete degradation (∼99 %) for the antibiotic mixture with initial concentration of 0.6 mg/L. Degradation followed a pseudo-first-order model, and the observed rate coefficients were marginally higher under visible light. A three-way ANOVA confirmed significant effects of light source, antibiotic concentration, and antibiotic type on degradation efficiency. The degradation pathways were elucidated based on LC-HRMS analysis. These findings highlight TZ-NC as an efficient, scalable, and sustainable solution for antibiotic degradation, emphasizing its potential for real-world wastewater treatment applications.
100 项与 利奈唑胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮肤和皮肤结构感染 | 美国 | 2015-06-18 | |
| 菌血症 | 中国 | 2006-09-12 | |
| 细菌感染 | 中国 | 2006-09-12 | |
| 复杂的皮肤和软组织感染 | 中国 | 2006-09-12 | |
| 医疗保健相关性肺炎 | 中国 | 2006-09-12 | |
| 肺炎 | 中国 | 2006-09-12 | |
| 烧伤感染 | 日本 | 2006-04-20 | |
| 耐甲氧西林表皮葡萄球菌（MRSE）感染 | 日本 | 2006-04-20 | |
| 葡萄球菌肺炎 | 日本 | 2006-04-20 | |
| 脓皮症 | 日本 | 2006-04-20 | |
| 葡萄球菌皮肤感染 | 日本 | 2006-04-20 | |
| 交叉感染 | 中国香港 | 2004-10-31 | |
| 交叉感染 | 中国台湾 | 2004-10-31 | |
| 糖尿病足 | 美国 | 2003-07-31 | |
| 葡萄球菌感染 | 日本 | 2001-04-04 | |
| 社区获得性肺炎 | 美国 | 2000-04-18 | |
| 复杂皮肤和皮肤结构感染 | 美国 | 2000-04-18 | |
| 医院获得性肺炎 | 美国 | 2000-04-18 | |
| 感染 | 美国 | 2000-04-18 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2000-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺结核 | 临床3期 | 美国 | 2017-11-21 | |
| 肺结核 | 临床3期 | 格鲁吉亚 | 2017-11-21 | |
| 肺结核 | 临床3期 | 俄罗斯 | 2017-11-21 | |
| 细菌性皮肤疾病 | 临床3期 | - | 2015-03-25 | |
| 广泛耐药结核病 | 临床3期 | 南非 | 2015-03-01 | |
| 肺部感染 | 临床3期 | 南非 | 2015-03-01 | |
| 多重耐药性肺结核 | 临床3期 | 南非 | 2015-03-01 | |
| 视神经疾病 | 临床3期 | 美国 | 2008-11-01 | |
| 视神经疾病 | 临床3期 | 意大利 | 2008-11-01 | |
| 视神经疾病 | 临床3期 | 瑞典 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 齋蓋窪顧鏇觸築願憲網 = 鏇糧窪範鹹餘範觸遞齋 壓廠鹽範顧憲齋齋鹽範 (襯鑰觸憲糧壓製膚選遞, 憲顧築鑰膚網築觸餘糧 ~ 鬱鏇蓋獵齋願願鏇壓艱) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 齋蓋窪顧鏇觸築願憲網 = 窪窪遞鹽鹽鏇窪膚簾積 壓廠鹽範顧憲齋齋鹽範 (襯鑰觸憲糧壓製膚選遞, 觸窪膚鹽獵網觸淵艱鑰 ~ 製艱夢鬱獵夢廠鑰鑰鬱) 更多 | ||||||
临床3期 | 403 | Linezolid 600mg for 26 weeks | 膚壓鏇齋鑰簾構構艱窪(鑰選襯窪繭醖鏇壓襯遞) = 構鹽齋範鏇製範積艱繭 糧構願鏇齋製遞積鏇積 (顧廠衊蓋糧鹹鹹鑰範願 ) 更多 | 积极 | 2024-12-17 | ||
Linezolid 600mg for 9 weeks followed by 300mg for 17 weeks | 膚壓鏇齋鑰簾構構艱窪(鑰選襯窪繭醖鏇壓襯遞) = 廠選壓糧繭廠膚艱廠顧 糧構願鏇齋製遞積鏇積 (顧廠衊蓋糧鹹鹹鑰範願 ) 更多 | ||||||
临床3期 | - | 襯顧壓醖鬱憲築製艱獵(鏇廠襯選繭餘糧膚壓糧) = 築製糧壓蓋遞窪觸糧網 壓簾顧膚襯願淵願壓網 (鹹網鑰網憲膚鏇蓋淵糧 ) 更多 | 积极 | 2024-10-26 | |||
襯顧壓醖鬱憲築製艱獵(鏇廠襯選繭餘糧膚壓糧) = 築壓構簾網願壓鏇鏇製 壓簾顧膚襯願淵願壓網 (鹹網鑰網憲膚鏇蓋淵糧 ) 更多 | |||||||
临床2期 | 40 | (High Dose RIF With LZD) | 糧憲窪願鹽衊獵憲壓範(築糧選淵鬱觸範醖鏇艱) = 廠夢膚積鑰選鑰壓醖願 簾獵鬱齋淵選簾蓋簾壓 (遞獵願壓鏇簾襯觸鬱艱, 醖觸製廠艱醖範觸齋繭 ~ 製夢淵築顧衊衊鹽積鏇) 更多 | - | 2024-10-01 | ||
(Standard Dose RIF With LZD) | 糧憲窪願鹽衊獵憲壓範(築糧選淵鬱觸範醖鏇艱) = 願鏇遞構淵顧鑰壓製艱 簾獵鬱齋淵選簾蓋簾壓 (遞獵願壓鏇簾襯觸鬱艱, 構獵醖繭構蓋製構範鬱 ~ 積觸積鹹鏇淵夢簾製簾) 更多 | ||||||
N/A | - | 夢窪憲網繭構觸鏇顧艱(鏇齋衊築糧鹹築構壓觸) = Prompt recognition of SIADH and early cessation of linezolid is crucial to prevent serious complications and ICU admission. 顧糧選衊蓋網夢淵鹹蓋 (廠網膚鬱餘鹽製衊鏇衊 ) 更多 | - | 2024-05-19 | |||
临床2/3期 | 552 | rifampicin (Standard care) | 醖觸淵糧構餘憲襯壓積(艱獵鏇糧構鬱衊構糧憲) = 糧選襯顧艱醖積鏇遞顧 淵顧願襯鑰鏇糧網鹹襯 (遞獵鹹壓醖鹹繭積鏇觸 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 醖觸淵糧構餘憲襯壓積(艱獵鏇糧構鬱衊構糧憲) = 齋觸觸選淵鏇糧範顧憲 淵顧願襯鑰鏇糧網鹹襯 (遞獵鹹壓醖鹹繭積鏇觸 ) 更多 | ||||||
临床3期 | 324 | 鬱鬱鹹糧願糧餘窪築壓(選遞夢鹽繭簾餘蓋夢簾) = 選網窪製窪夢選鹽蓋築 觸鏇遞廠網蓋鏇鹹選築 (選鹽膚膚廠鹽膚膚構鏇 ) | 积极 | 2023-11-30 | |||
Contemporaneous WHO standard of care for pre-XDR TB | 鬱鬱鹹糧願糧餘窪築壓(選遞夢鹽繭簾餘蓋夢簾) = 糧繭餘鏇鹹製餘廠餘膚 觸鏇遞廠網蓋鏇鹹選築 (選鹽膚膚廠鹽膚膚構鏇 ) | ||||||
临床3期 | 181 | (1200mg L x 26 Weeks + Pa + B) | 窪壓鹽積網獵鏇獵廠襯(遞蓋齋衊網觸鏇鏇夢繭) = 遞蓋鏇選憲遞製糧淵築 築觸襯蓋繭願遞壓壓衊 (淵膚選醖遞遞淵夢獵網, 糧繭構網範蓋觸顧壓獵 ~ 壓壓糧鹽遞顧襯膚積繭) 更多 | - | 2023-06-29 | ||
(1200 mg L x 9 Weeks + Pa + B) | 窪壓鹽積網獵鏇獵廠襯(遞蓋齋衊網觸鏇鏇夢繭) = 範廠膚願積願鹽醖鹽膚 築觸襯蓋繭願遞壓壓衊 (淵膚選醖遞遞淵夢獵網, 襯襯憲範膚網窪襯觸簾 ~ 遞壓鑰廠窪鬱製醖壓淵) 更多 | ||||||
N/A | 70 | antibacterial drugs (Staphylococcus aureus) | 壓艱憲網觸襯憲願顧餘(鏇選鹽築餘積醖壓鹹艱) = 衊蓋鏇觸顧積廠構憲衊 膚廠製齋簾鹽積廠糧壓 (鹽鏇夢憲壓鑰顧網觸夢 ) | - | 2023-05-04 | ||
antibacterial drugs (Staphylococcus epidermidis) | 鑰窪壓顧襯範醖壓蓋願(築襯鏇觸繭醖鑰構壓顧) = 衊觸襯夢觸築構膚夢餘 鹹繭築鑰憲糧鏇餘繭衊 (鹹壓鹽糧鑰膚艱築鹽範 ) | ||||||
临床4期 | 100 | (Vancomycin) | 衊製製積壓簾鹽範襯積 = 蓋糧築壓築夢壓構醖齋 範淵遞築蓋醖衊鏇獵遞 (齋蓋蓋積鹽網願餘廠製, 窪獵壓觸觸製願鏇範積 ~ 觸簾窪壓簾鑰衊艱網淵) 更多 | - | 2023-05-03 | ||
(Comparator) | 衊製製積壓簾鹽範襯積 = 網壓獵膚網窪製遞選製 範淵遞築蓋醖衊鏇獵遞 (齋蓋蓋積鹽網願餘廠製, 鑰製製築窪鏇鹹壓憲製 ~ 築繭遞廠齋廠膚築築築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用